GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Avicanna Inc (TSX:AVCN) » Definitions » EBITDA Margin %

Avicanna (TSX:AVCN) EBITDA Margin % : 5.21% (As of Dec. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Avicanna EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Avicanna's EBITDA for the three months ended in Dec. 2024 was C$0.35 Mil. Avicanna's Revenue for the three months ended in Dec. 2024 was C$6.62 Mil. Therefore, Avicanna's EBITDA margin for the quarter that ended in Dec. 2024 was 5.21%.


Avicanna EBITDA Margin % Historical Data

The historical data trend for Avicanna's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avicanna EBITDA Margin % Chart

Avicanna Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only -2,146.43 -462.80 -300.79 -43.80 -9.54

Avicanna Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -44.14 -10.16 -26.03 -8.22 5.21

Competitive Comparison of Avicanna's EBITDA Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Avicanna's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Avicanna's EBITDA Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Avicanna's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Avicanna's EBITDA Margin % falls into.


;
;

Avicanna EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Avicanna's EBITDA Margin % for the fiscal year that ended in Dec. 2024 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2024 )/Revenue (A: Dec. 2024 )
=-2.43/25.459
=-9.54 %

Avicanna's EBITDA Margin % for the quarter that ended in Dec. 2024 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2024 )/Revenue (Q: Dec. 2024 )
=0.345/6.617
=5.21 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Avicanna  (TSX:AVCN) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Avicanna EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Avicanna's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Avicanna Business Description

Traded in Other Exchanges
Address
480 University Avenue, Suite 1502, Toronto, BC, CAN, M5G 1V2
Avicanna Inc is an innovative, commercial-stage, and international biopharmaceutical company focused on the development, advancement, and commercialization of evidence-based cannabinoid-based products for the global consumer, as well as medical and pharmaceutical market segments. In global cannabinoid advancements, it conducts most of its research in Canada at its research and development headquarters in JLABS in Toronto, located in the MaRS Discovery District. The company actively collaborates with Canadian academic and medical institutions. Avicanna has established a scientific platform including research and development and clinical development which led to the commercialization of more than twenty products across four main market segments.
Executives
Sheldon Inwentash 10% Security Holder
Threed Capital Inc. 10% Security Holder
Phillip Cardella Senior Officer
Aras Azadian Director, Senior Officer
Davender Sohi Senior Officer
David White Director
Kyle Lawrence Langstaff Director or Senior Officer of Insider or Subsidiary (other than in 4,5,6)
Chandra Panchal Director
Janet Giesselman Director

Avicanna Headlines

No Headlines